Suraksha Diagno.

Why is Suraksha Diagnostic Ltd falling/rising?

As of 25-Aug, Suraksha Diagnostic Ltd's stock price is at Rs 317.60, down 1.9% and part of a two-day decline totaling 2.19%. Despite strong fundamentals, recent market sentiment is negative, leading to decreased investor participation and volatility.

As of 25-Aug, Suraksha Diagnostic Ltd's stock price is falling, currently at Rs 317.60, which reflects a decrease of Rs 6.15 or 1.9%. This decline is part of a broader trend, as the stock has been losing value for the last two days, resulting in a total drop of 2.19% during this period. Additionally, the stock has underperformed its sector by 3.01% today.<BR><BR>The stock is also close to its 52-week high, being only 4.59% away from Rs 333.65, but it touched an intraday low of Rs 313.5, indicating significant volatility. Furthermore, there has been a notable decrease in investor participation, with delivery volume on 24 August falling by 42.36% compared to the 5-day average, suggesting reduced interest from investors.<BR><BR>Despite these negative factors, the company has shown strong fundamentals, including a low Debt to EBITDA ratio of 1.40 times and healthy long-term growth in operating profit. However, the recent price movement indicates that current market sentiment is leaning towards selling, contributing to the stock's decline.

Which are the latest news on Suraksha Diagno.?

Should I buy, sell or hold Suraksha Diagnostic Ltd?

What does Suraksha Diagno. do?

Suraksha Diagnostic Ltd is a micro-cap healthcare services company that reported net sales of 88 Cr and a net profit of 13 Cr for June 2026. It has a market cap of INR 1,581 Cr and key financial metrics include a P/E ratio of 45.00 and a debt-equity ratio of 0.42.

Overview:<BR>Suraksha Diagnostic Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>Suraksha Diagnostic Ltd was incorporated as 'Suraksha Diagnostic Private Limited' on March 15, 2005. It later converted to a public limited company and changed its name to 'Suraksha Diagnostic Limited', receiving a fresh certificate of incorporation on July 16, 2024. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 88 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 13 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 1,581 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 45.00<BR>- Industry P/E: 67<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 0.42<BR>- Return on Equity: 13.15%<BR>- Price to Book: 5.72<BR><BR>Contact Details:<BR>Details: No Company Details Available<BR>Registrar Address: Not available.

Who are the peers of the Suraksha Diagno.?

Suraksha Diagno.'s peers include Suven Life Sciences, Vimta Labs, Krsnaa Diagnostics, Tarsons Products, One Global Services, Laxmi Dental, 3B Blackbio, and Health X Platform. Suraksha Diagno. has good ratings in management risk, growth, and capital structure, with a 1-year return of 1.98%, significantly lower than One Global Services' 121.51% but higher than Krsnaa Diagnostics' -30.98%.

Peers: The peers of Suraksha Diagno. are Suven Life Scie., Vimta Labs, Krsnaa Diagnost., Tarsons Products, One Global Serv, Laxmi Dental, 3B Blackbio, and Health X Platfor.<BR><BR>Quality Snapshot: Excellent management risk is observed at One Global Serv and Laxmi Dental, while Average management risk is found at Vimta Labs, Krsnaa Diagnost., and 3B Blackbio, and the rest. Below Average management risk is noted at Suven Life Scie., Tarsons Products, and Health X Platfor. Growth is rated as Excellent for One Global Serv, Average for Vimta Labs, Krsnaa Diagnost., and Laxmi Dental, and Below Average for Suven Life Scie., Tarsons Products, 3B Blackbio, and Health X Platfor. Suraksha Diagno. stands out with Good ratings in Management Risk, Growth, and Capital Structure.<BR><BR>Return Snapshot: One Global Serv has the highest 1-year return at 121.51%, while Krsnaa Diagnost. has the lowest at -30.98%. Suraksha Diagno.'s 1-year return is 1.98%, which is significantly lower than One Global Serv's but higher than Krsnaa Diagnost.'s. Additionally, Krsnaa Diagnost., Laxmi Dental, and 3B Blackbio have negative six-month returns.

How big is Suraksha Diagno.?

As of 14th August, Suraksha Diagnostic Ltd has a market capitalization of 1,598.88 Cr, with recent net sales of 325.48 Cr and net profit of 35.80 Cr over the last four quarters.

As of 14th August, <BR><BR>Market Cap: Suraksha Diagnostic Ltd has a market capitalization of 1,598.88 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 325.48 Cr, while the sum of Net Profit for the same period is 35.80 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 211.24 Cr, and Total Assets amount to 333.52 Cr.

Are Suraksha Diagnostic Ltd latest results good or bad?

Suraksha Diagnostic Ltd's latest results show strong revenue growth with record net sales of ₹81.41 crores, up 25.07% year-on-year. However, profitability has declined significantly, with net profit falling 16.49% quarter-on-quarter, raising concerns about operational efficiency.

Suraksha Diagnostic Ltd's latest results present a mixed picture. On the positive side, the company achieved record net sales of ₹81.41 crores, reflecting a sequential growth of 4.79% and a year-on-year increase of 25.07%. This indicates strong demand for its diagnostic services and effective market penetration.<BR><BR>However, profitability has come under significant pressure. The net profit for the quarter fell to ₹6.28 crores, down 16.49% quarter-on-quarter and 15.02% year-on-year. Additionally, both the operating profit margin and the profit after tax (PAT) margin contracted, with the PAT margin dropping to 7.57% from 9.32% in the previous quarter. Rising interest costs and a higher effective tax rate have contributed to these declines, raising concerns about the company's operational efficiency and cost management.<BR><BR>In summary, while the revenue growth is commendable, the sharp decline in profitability metrics suggests underlying challenges that could impact the company's financial health moving forward.

When is the next results date for Suraksha Diagnostic Ltd?

The next results date for Suraksha Diagnostic Ltd is 21 May 2026.

The next results date for Suraksha Diagnostic Ltd is scheduled for 21 May 2026.

Is Suraksha Diagno. overvalued or undervalued?

As of October 14, 2025, Suraksha Diagnostics is considered overvalued with a PE ratio of 45.39, a Price to Book Value of 7.08, and an EV to EBITDA of 18.26, all significantly above industry norms, while its stock has underperformed the Sensex with a year-to-date return of -22.4%.

As of 14 October 2025, the valuation grade for Suraksha Diagnostics has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued. Key ratios highlight this assessment: the PE ratio stands at 45.39, the Price to Book Value is 7.08, and the EV to EBITDA is 18.26, all of which are significantly higher than industry norms.<BR><BR>In comparison to its peers, Suraksha Diagnostics' PE ratio is notably lower than that of Max Healthcare, which has a PE of 93.68, and higher than Apollo Hospitals, which is valued at 70.7. The PEG ratio for Suraksha is 0.00, suggesting a lack of growth expectations compared to its price, further reinforcing the overvaluation stance. Additionally, the company's stock has underperformed against the Sensex, with a year-to-date return of -22.4% compared to the Sensex's 4.98%, which underscores the potential disconnect between its current valuation and market performance.

How has been the historical performance of Suraksha Diagno.?

Suraksha Diagno has shown positive financial growth over the past two years, with net sales increasing to 252.09 Cr in March 2025 from 218.71 Cr in March 2024, and profit after tax rising to 30.98 Cr from 23.13 Cr, reflecting improved profitability and a stable financial position.

Answer:<BR>The historical performance of Suraksha Diagno shows a positive trend in key financial metrics over the past two years.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Suraksha Diagno reported net sales of 252.09 Cr, an increase from 218.71 Cr in March 2024. The total operating income mirrored this growth, reaching 252.09 Cr, while total expenditure (excluding depreciation) rose to 170.85 Cr from 148.64 Cr. Operating profit, excluding other income, improved to 81.24 Cr from 70.07 Cr, leading to an operating profit margin of 32.23%, slightly up from 32.04%. Profit before tax also saw a significant increase to 41.41 Cr from 31.45 Cr, resulting in a profit after tax of 30.98 Cr, compared to 23.13 Cr the previous year. This reflects a PAT margin increase to 12.29% from 10.58%. The company's total assets grew to 333.52 Cr from 300.20 Cr, while total liabilities increased to 333.52 Cr from 300.20 Cr, indicating a stable financial position. Cash flow from operating activities improved to 63.00 Cr from 60.00 Cr, contributing to a consistent closing cash balance of 2.00 Cr over the last two years. Overall, Suraksha Diagno has demonstrated solid growth in revenue and profitability, alongside a stable asset and liability structure.

Is Suraksha Diagno. technically bullish or bearish?

As of June 23, 2025, the market for Suraksha Diagno is in a neutral stance with no clear direction, as indicated by mixed signals from key technical indicators like MACD, RSI, and moving averages.

As of 23 June 2025, the technical trend has changed from mildly bullish to sideways. The current stance is neutral, reflecting a lack of clear direction. The MACD shows no signal on both the weekly and monthly time frames, while the RSI also indicates no signal on the weekly and monthly. The Bollinger Bands are mildly bullish on the weekly but do not provide strong confirmation. Moving averages, KST, Dow Theory, and OBV show no trends, further supporting the neutral stance. Overall, the indicators suggest indecision in the market for Suraksha Diagno.

Who are the top shareholders of the Suraksha Diagno.?

The top shareholders of Suraksha Diagno include Ritu Mittal with 15.89%, Orbimed Asia II Mauritius Limited at 12.88%, mutual funds with 19.26%, foreign institutional investors holding 14.46%, and individual investors at 13.52%.

The top shareholders of Suraksha Diagno include the promoters, who hold the majority of shares. The promoter with the highest holding is Ritu Mittal, owning 15.89%. Additionally, Orbimed Asia II Mauritius Limited is the highest public shareholder with a stake of 12.88%. Mutual funds collectively hold 19.26% through 8 schemes, while foreign institutional investors (FIIs) hold 14.46% across 10 entities. Individual investors account for 13.52% of the shareholding.

Has Suraksha Diagno. declared dividend?

No Dividend History Available